Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data ...

CEO John Houston emphasized that Arvinas is nearing key milestones, including the first Phase 3 topline data for vepdegestrant (vepdeg) from the VERITAC-2 trial expected in Q1 2025. He noted that this ...

As part of Arvinas global collaboration with Pfizer, the companies plan to: Announce topline data for the VERITAC-2 Phase 3 monotherapy cli ...

The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection.Golden, CO, Feb. 10, 2025 (GLOBE ...

The clinical trial, known as the CDK4/6 Inhibitor Dosing Knowledge Study, is investigating personalized dosing strategies for ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...